Evaluations were made based on HbA1c levels, occurrences of hypoglycemia, ketoacidosis, and other complications.<h4>Results</h4> The study revealed significant improvements in HbA1c levels in the basal-bolus insulin group compared to premixed insulin patients three and six months after treatment (p=0.048 and p=0.005, respectively). The gene discussed is INS; the disease is Hypoglycemia.